QUEBEC CITY, Aug. 15, 2016 /CNW Telbec/ - Opsens Inc.
("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF)
announced today that OptoWire's performance was highlighted in the
Circulation Journal, the Official Journal of the Japanese
Circulation Society.
The article, written jointly by Dr. Nico HJ Pijls and Dr.
Bernard de Bruyne is called
"Fractional Flow Reserve, Coronary Pressure Wires, and Drift". The
article highlights the fact that traditional guidewires showed an
inevitable drift of the measure, despite major efforts to minimize
it. It is said that the occurrence of drift is the most annoying
problem that can occur during a procedure in a patient because it
is often unnoticed before the wire is pulled back to the guiding
catheter at the end of the procedure, and if it is present, it may
invalidate the measurement. In the article, it is mentioned
that in their laboratories, they used approximately 100 OptoWire in
the past year and they have not observed any drift in any of the
OptoWire up to now.
Opsens commercialized the OptoWire, an optical guidewire to
measure the Fractional Flow Reserve ("FFR"). This measurement is
used to optimize the diagnosis and guide the treatment of patients
with coronary heart disease.
"Opsens is honored to see a significant strength of its patented
optical pressure guidewire such as the accuracy of the measurement
being recognized by the founding fathers of FFR. In the future,
Opsens aims to contribute to FFR growth by providing
high-performance products to the cardiology community "said
Louis Laflamme, President and CEO of
Opsens.
Opsens aims to become a key player in the guidewire FFR market
with the OptoWire, a nitinol-based optical guidewire. The OptoWire
provides intra-coronary blood pressure measurements with unique,
patented optical pressure guidewire technologies. It is immune to
adverse effects related to blood contact, and allows easy and
reliable connectivity that leads to reliable FFR measurements in
extended conditions of usage. The OptoWire is also designed to
provide cardiologists with a guidewire that provides optimal
performance to navigate coronary arteries and cross blockages with
ease and safety. Based on industry sources, the FFR market
represented more than US$300 million
in sales in 2014 and is expected to reach US$1 billion in the medium-term.
About Opsens Inc. (www.opsens.com or
www.opsensmedical.com)
Opsens focuses mainly on the measure of FFR in interventional
cardiology. Opsens offers an advanced optical-based pressure
guidewire (OptoWire) that aims at improving the clinical outcome of
patients with coronary artery disease. Opsens is also involved in
industrial activities. The Company develops, manufactures and
installs innovative fibre optic sensing solutions for critical
applications such as the monitoring of oil wells and other
demanding industrial applications.
Forward-looking statements contained in this press release
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance and achievements of
Opsens to be materially different from any future results,
performance or achievements expressed or implied by the said
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE OPSENS INC.